TIS tissue therapies limited

"It is possible that the MHRA review may result in a further...

  1. 347 Posts.
    "It is possible that the MHRA review may result in a further referral to the European Medicines Agency (EMA) for a review of the VitroGro® ECM manufacturing process."

    A possible additional barrier mentioned by SM in the announcement, but not explained or given any context.

    Another review of the manufacturing process??

    Under what circumstances? How likely? How long?

    SM should be asking these questions now so he can be prepared for the worst.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.